Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $40.62 down -0.56% from its previous closing price of $40.85. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 0.84 million shares were traded. KYMR stock price reached its highest trading level at $40.91 during the session, while it also had its lowest trading level at $39.54.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 8.49. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Morgan Stanley Upgraded its Equal-Weight to Overweight on June 03, 2025, while the target price for the stock was maintained at $79.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 30 ’25 when BVF PARTNERS L P/IL bought 317,167 shares for $44.00 per share. The transaction valued at 13,955,348 led to the insider holds 2,798,795 shares of the business.
BAKER BROS. ADVISORS LP bought 655,500 shares of KYMR for $28,842,000 on Jun 30 ’25. The Director now owns 6,117,295 shares after completing the transaction at $44.00 per share. On Jun 11 ’25, another insider, Ridloff Elena, who serves as the Director of the company, sold 4,500 shares for $50.00 each. As a result, the insider received 225,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2849785344 and an Enterprise Value of 2268336896. For the stock, the TTM Price-to-Sale (P/S) ratio is 48.40 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 38.521 whereas that against EBITDA is -8.35.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.19, which has changed by -0.04423529 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is -8.69%, while the 200-Day Moving Average is calculated to be 3.81%.
Shares Statistics:
For the past three months, KYMR has traded an average of 835.30K shares per day and 550890 over the past ten days. A total of 65.11M shares are outstanding, with a floating share count of 58.31M. Insiders hold about 16.89% of the company’s shares, while institutions hold 91.13% stake in the company. Shares short for KYMR as of 1752537600 were 7572642 with a Short Ratio of 9.07, compared to 1749772800 on 7582895. Therefore, it implies a Short% of Shares Outstanding of 7572642 and a Short% of Float of 13.38.
Earnings Estimates
Kymera Therapeutics Inc (KYMR) is currently under the scrutiny of 16.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.56 and low estimates of -$1.29.
Analysts are recommending an EPS of between -$2.82 and -$4.25 for the fiscal current year, implying an average EPS of -$3.49. EPS for the following year is -$4.0, with 18.0 analysts recommending between -$1.91 and -$6.46.
Revenue Estimates
A total of 21 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $190M, while the lowest revenue estimate was $22.1M, resulting in an average revenue estimate of $79.96M. In the same quarter a year ago, actual revenue was $47.07M
